About DRAXIS

Directors and Officers

Directors

Brian M. King1
Brian King is Chairman of DRAXIS Health Inc. He is the former Chairman and CEO of Connaught Biosciences, Inc. He is also a director and Chairman of the Compensation Committee of Onex Corporation and a director and member of the Investment, Valuation and Audit Committees of VenGrowth Investment Funds.
Leslie L. Dan
Leslie Dan is Chairman of Novopharm Limited, one of Canada's leading pharmaceutical companies and Chairman of Viventia Biotech Inc. Prior to April 5, 2000, Mr. Dan was Chairman and CEO of Novopharm Limited.
George M. Darnell2,3
George Darnell is the retired President of the Dade Division and the Executive Vice President of the Baxter Diagnostics Group of Baxter International. He has 35 years of U.S. and international experience in the diagnostic industry.
Rolf H. Henel2,3
Rolf Henel is the retired President of Cyanamid International, Lederle Division. He currently serves as an advisor to the healthcare industry and is a partner in Naimark & Associates, a healthcare consulting firm. He is also a director and member of the Audit and Nominating and Corporate Governance Committees of SciClone Pharmaceuticals, Inc. and a director, Chair of the Compensation Committee and member of the Audit Committee of Penwest Pharmaceuticals Co.
Samuel W. Sarick2
Samuel Sarick is President of Samuel Sarick Limited, a company with long-standing involvement in commercial property development.
Bruce W. Simpson1,2
Bruce Simpson served as the President of the Genpharm division of E Merck, the President and CEO of Medeva Pharmaceuticals in the U.S. and in senior management positions at Fisons Corporation. He currently heads a private consulting firm specializing in marketing and business development within the healthcare industry and is a director of Hi-Tech Pharmacal Co., Inc.
John A. Vivash1,3
John Vivash was formerly President and CEO of CIBC Securities Inc., Fidelity Investments Canada Limited and Manulife Securities International Ltd. He currently serves as President and CEO of Tesseract Financial Inc., a financial services consultancy; director and member of the Audit Committee and Chair of the Nominating and Corporate Governance Committee of Sierra Systems Group Inc.; and Chairman of the Board and member of the Compensation Committee of Financial Models Company Inc. He is also a member of the Board, the Audit Committee and the Conduct Review Committee of State Street Trust Company Canada and is a member of the Board of Eastmain Resources Inc.
 
1 Member of the Human Resources and Compensation Committee
2 Member of the Audit Committee
3 Member of the Nominating and Corporate Governance Committee
 
 

See Also:

Corporate Governance

Charter of the Board of Directors

Charter of the Audit Committee

Charter of the Nominating and Corporate Governance Committee

Charter of the Human Resources and Compensation Committee

Code of Ethics and Business Conduct


Officers
Dan Brazier
President and Chief Executive Officer
Officer since 1998.
Mr. Brazier is President and Chief Executive Officer of the Company. He previously served more than two years as Chief Operating Officer. Prior to that he was Senior Vice President of Corporate Development and Strategic Planning, where he worked closely with the operating divisions and was responsible for establishing the current strategic plan for the Company. Prior to 2003 he was President of the company’s specialty pharmaceuticals business focused in neurology. Mr. Brazier has nearly 30 years experience in consumer marketing, healthcare and pharmaceutical companies in increasingly responsible senior management positions with responsibilities in Canada, the United States and internationally. Mr. Brazier holds an Honours degree in Commerce, majoring in Marketing and Finance.
Jean-Pierre Robert       
Chief Operating Officer and President of DRAXIS Specialty Pharmaceuticals Inc.
Officer since April 2005
Mr. Robert, B.Sc., is President of Draxis Specialty Pharmaceuticals Inc. Prior to joining DRAXIS, he served as Vice President and General Manager of Tyco Healthcare (Canada), overseeing domestic and export operations, following its acquisition of Mallinckrodt (Canada), where he held the same position. Most recently, Mr. Robert was President and CEO of an emerging Canadian biopharmaceutical company. He has extensive healthcare industry experience including executive, general management, marketing and sales roles involving diagnostic, pharmaceutical, chemical and laboratory products with Mallinckrodt, Fisher Scientific, Hoechst and Bayer. He holds a B.Sc. and was a member of the Canadian Society of Nuclear Medicine.
Alida Gualtieri
General Counsel and Secretary
Officer since November 2003.
Ms. Gualtieri joined the Company in November 2003 as General Counsel and Secretary. Prior to joining the Company, she was a partner in the Corporate Finance Mergers & Acquisitions sector of McCarthy Tétrault LLP in Montreal, Quebec, Canada’s largest law firm. Between March 1996 and August 1999, Ms. Gualtieri was Legal Counsel at Fonds de Solidarité des Travailleurs du Québec (F.T.Q.), Canada’s largest labor-sponsored venture capital fund. Ms. Gualtieri earned her BCL and LLB law degrees at McGill University in 1987 and was admitted to the Bar of the Province of Quebec in 1988.
Mark Oleksiw
Chief Financial Officer
Officer since July 2003.
Mr. Oleksiw became Chief Financial Officer on July 1, 2003. He joined DRAXIS as Director of Finance in July 2002 after eight years with an international accounting firm, most recently as a senior manager with a focus on U.S. and Canadian publicly listed life science and technology companies. He also spent three years with Bell Canada and BCE Inc. with responsibility for external reporting, plus two years as a senior internal auditor at McGill University. Mr. Oleksiw is a Chartered Accountant and earned his Graduate Diploma in Public Accountancy and B. Com. from McGill University.
Jerry Ormiston       
Officer since May 2001.
Mr. Ormiston, B.Sc., MBA, joined DRAXIS in May 2001 as Executive Director, Investor Relations following a two-year stint as a senior consultant in a Toronto investor relations firm working with small and mid-sized entrepreneurial companies on capital markets communications strategies. Prior to that he was at Allelix Biopharmaceuticals for 12 years – four as Manager of Investor Relations and eight in the business development area. He has 25 years experience in the healthcare industry in pharmaceuticals and biotechnology. His assignments over those years have included positions in business development, marketing, corporate communications, production management, quality assurance and regulatory affairs.